Merck (NYSE:MRK) reached a historic milestone in oncology today as the FDA approved KEYTRUDA (pembrolizumab) and its new subcutaneous twin, KEYTRUDA QLEX, for the treatment of platinum-resistant ovarian cancer.
Agilent Technologies (NYSE:A) announced today that the U.S. Food and Drug Administration (FDA) has approved its PD-L1 IHC 22C3 pharmDx as the first and only companion diagnostic to identify first-line patients with epithelial ovarian cancer (EOC) eligible for Merck’s blockbuster immunotherapy, KEYTRUDA.
Kornit Digital (NASDAQ:KRNT) marked a major structural turning point in 2025, successfully transitioning its business from one-time equipment sales to a resilient recurring revenue model.
In times of uncertainty, we often look for something solid to hold onto. Lately, it seems the world’s investors have decided that “something solid” is, quite literally, gold.
The metal’s soaring price is more than just a market trend; it's a global barometer of anxiety.
When faith in currencies, governments, and traditional financial systems begins to waver, we see a familiar flight to the perceived safety of this timeless asset.
Well, pull out the party hats and dust off the stock tickers.
Lithium, the commodity that investors and analysts had all but left for dead in the great market purge of 2023-2024, is back.
The stock market has long treated Tesla (NASDAQ:TSLA) less as a traditional automaker and more as a futuristic technology cult, with its valuation soaring on the gravitational pull of its CEO, Elon Musk.
This persistent "Musk Premium" has burned countless short-sellers.
Bitcoin has vaporised more than US$800 billion in its latest crash and sucked US$1 trillion out of the broader crypto market.
With nearly US$2 trillion in market value and rising allocations from Wall Street firms, ETFs, pension funds, and insurers, Bitcoin is increasingly woven into traditional finance.
Trump used his Davos speech to tout US economic dominance, promote crypto, and revive his push for Greenland.
Japan’s bond market has been sliding all week, with the 10-year yield now near 2.37% and the 40-year pushing above 4.2%, both multi-decade highs.
U.S. President Donald Trump has escalated his confrontation with European leaders on the eve of the World Economic Forum in Davos, threatening to impose a 200% tariff on French wine and champagne.
AstraZeneca (NASDAQ:AZN) reported fourth-quarter and full-year 2025 results on Tuesday that failed to meet Wall Street’s expectations, as a surge in operating costs for its expanding drug pipeline dampened the impact of double-digit sales growth in its oncology division.
Harley-Davidson(NYSE:HOG) shares fell more than 8% on Tuesday, February 10, 2026, after the company issued a cautious 2026 outlook that signaled another year of stabilization rather than a return to rapid growth.
The Coca-Cola Company (NYSE:KO) reported fourth-quarter and full-year 2025 results on Tuesday, February 10, 2026, showcasing the strength of its global "all-weather" strategy.
CVS Health (NYSE:CVS) reported on Tuesday, February 10, 2026, that it has become the first pure-play healthcare company to surpass $400 billion in annual revenue, even as a series of heavy one-time charges masked the underlying strength of its Aetna and Caremark units.